Wall Street Zen upgraded shares of Davion Healthcare (NASDAQ:DAVI – Free Report) to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.
Davion Healthcare Stock Performance
Shares of NASDAQ:DAVI opened at $1.49 on Friday. Davion Healthcare has a 12 month low of $1.46 and a 12 month high of $12.30.
Davion Healthcare Company Profile
Davion Healthcare Plc is a digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments. The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion Healthcare Plc is based in DUBLIN.
Further Reading
- Five stocks we like better than Davion Healthcare
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Davion Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davion Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
